Category:
Prophylactic Biological Products
CAS NO:
179324-69-7
Standard:
In-house Standards,

Bortezomib is the first proteasome inhibitor approved by the U.S. FDA for multiple myeloma, a blood cancer. Reversible inhibitor of 26S proteasome, a bark-shaped polyprotein particle, found in the nucleus and cytoplasm of all eukaryotic cells. Targeting the ubiquitin-proteasome pathway.